Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia

Wulyo Rajabto, Ary Harryanto Reksodiputro, Ikhwan Rinaldi, Hilman Tadjoedin, Dimas Priantono, Yohana Kusuma Angkasa

Research output: Contribution to journalArticlepeer-review


Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome and BCR-ABL fusion oncogene. CML is one of the illnesses that may be treated using Tyrosine Kinase Inhibitors (TKIs), a type of targeted therapy. Since TKIs are the standard of therapy, long-term survival of CML has improved compared to chemotherapy and interferon-alpha. For the first-line treatment for CML, there are four commercially available TKIs that serve as an integral part of the disease management. However, there are many challenges in diagnosing, treating, and monitoring patients with chronic phase CML in Indonesia. This study highlights the epidemiology data of chronic phase CML patients, particularly at Dr. Cipto Mangunkusumo General Hospital, an Indonesian national referral hospital, and how to diagnose, select first-line TKIs, and monitor the response of treatment after TKIs administration.

Original languageEnglish
Pages (from-to)530-536
Number of pages7
JournalSiriraj Medical Journal
Issue number8
Publication statusPublished - Aug 2022


  • Chronic phase chronic myeloid leukemia
  • diagnosis
  • epidemiology
  • monitoring
  • treatment


Dive into the research topics of 'Chronic Myeloid Leukemia (CML) at National Referral Hospital in Indonesia'. Together they form a unique fingerprint.

Cite this